Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c
November 8, 2018 4:04 PM ESTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $375 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.
... More